ASH News Daily - Saturday, December 10, 2011 - (Page C-7)

Saturday, December 10, 2011 ASH NewS DAily Cuisine: Chinese Fusion Price: $$ Attire: Casual Open for: Lunch served Mon.Sat. 11:30 a.m. to 2:30 p.m. Dinner served Sun.-Thurs. from 4:00 to 9:30 p.m., Fri. and Sat. 4:00 to 10:00 p.m. Voted “Best Chinese Food in San Diego,” Del Mar Renezvous offers an extensive menu including 45 vegetarian items, 29 vegan items, and a 40-item gluten-free menu. Dobson’s 956 Broadway Circle 619- 231-6771 www.dobsonsrestaurant.com/home Cuisine: California with a touch of Italian, French, Spanish, and Asian cuisine Price: $$ Attire: Semi-formal Open for: Lunch served Mon.-Fri. from 11:30 a.m. to 3:00 p.m. Dinner served Mon.-Wed. from 3:00 to 10:00 p.m., Thurs.-Fri. from 3:00 to 11:00 p.m. Page C–7 ® SAn diego trAvel guide Dining A popular choice among the downtown politicos, area business people, and convention attendees, Dobson’s is renowned for its mussel bisque, veal sweetbreads, lamb, and fresh fish specials. Donovan’s of Downtown 570 K Street 619- 237-9700 www.donovanssteakhouse.com Cuisine: Steak Price: $$$ Attire: Business casual (no shorts or flip-flops) Open for: Dinner served Mon.»» DINING Page C-14 «« From Page C-6 Sun.-Thurs. from 5:00 to 9:30 p.m., Fri. and Sat. from 5:00 to 10:30 p.m. Offering an array of North Indian authentic and exotic North Indian cuisine, this winner of “Best Vegetarian Restaurant” and “Best Indian Restaurant in San Diego,” promises a culinary feast feast of flavors. Café-21 750 5th Avenue 619- 795-0721 www.cafe-21.com Cuisine: Azerbaijan (Eurasian) Price: $ Attire: Casual Open for: Breakfast/lunch served Tues.-Sat. from 8:00 a.m. to 4:00 p.m., Sun. from 8:00 a.m. to 3:00 p.m. Dinner served Tues.-Sat. from 3:00 to 10:00 p.m., Fri. and Sat. 3:00 to 11:00 p.m. Choose from a menu that includes signature homemade bread sandwiches and organic salads replete with seasonal, locally grown, and preferably organic ingredients at Café-21. Café Sevilla 353 Fifth Avenue 619-233-5979 www.cafesevilla.com Cuisine: Spanish Price: $ Attire: Casual/business casual Open for: Dinner served Mon.Thurs. from 5:00 to 11:00 p.m., Fri.Sat. from 5:00 p.m. to 12:00 midnight Listen to live Spanish music as you enjoy a Spanish ambience in the restaurant and tapas bar. Go on a weekend for the Flamenco dinner show and witness authentic Flamenco and gypsy musicians and dancers. Candelas 416 3rd Avenue 619-702-4455 www.candelas-sd.com Cuisine: Mexican Price: $-$$ Attire: Casual Open for: Dinner served daily from 5:00 to 11:00 p.m. Boasting the “best that Latin culture has to offer,” Candelas strives to provide patrons with a “Chilango” experience and a Mexico City-type flavor. Del Mar Rendezvous 1555 Camino Del Mar, Suite #102 Del Mar 858-755-2669 www.delmarrendezvous.com Price Guide (Averages) $ $$ $$$ $$$$ Under $25 $25 to $50 $50 to $75 $75 to $100 Vosaroxin and Ara-C combination evaLuating Overall survival in Relapsed/refractory AML N OW ENROLLING! Pivotal Phase 3, randomized, controlled, double-blind, multinational clinical trial evaluating efficacy and safety of vosaroxin (VŌZ-ah-rox-in)—a first-in-class anticancer quinolone derivative (AQD)—plus cytarabine vs. placebo plus cytarabine for patients with first relapsed or refractory acute myeloid leukemia (AML). 90% power to detect a 40% improvement in overall survival. Innovative, adaptive trial design allows for a one-time sample size adjustment by the Data Safety Monitoring Board at the interim analysis to ensure adequate power across a broader range of clinically meaningful and statistically significant survival outcomes. Vosaroxin dose and schedule: 90 mg/m2 10-minute infusion or placebo on days 1 and 4; cytarabine (IDAC) 1 g/m2 given as a 2-hour IV infusion on days 1 through 5. Designed from results of a Phase 2 trial of the vosaroxin/cytarabine combination in 36 first relapsed [median CR1 duration of 7.3 months] and 33 primary refractory [median of 2 prior cycles (range of 1-6)] AML patients. For this Phase 2 trial, the median overall survival was 7.1 months, the combined complete remission rate was 28% (CR rate 25%), and the leukemia-free survival was 25 months. The 30-day and 60-day all-cause mortality was low at 3% and 9%, respectively. Infection-related toxicities were the most common Grade 3 or higher nonhematologic adverse events.1,2 VALOR Endpoints and Entry Criteria Primary endpoint Secondary endpoints Major entry criteria Overall survival CR rate Safety and tolerability At least 18 years of age ECOG performance status of 0-2 First relapse (CR duration between 90 days and 24 4 months) OR refractory (CR duration ≤90 days or refractory to 1 or 2 prior induction therapies) CR=complete remission by International Working Group (IWG) response criteria; ECOG=Eastern Cooperative Oncology Group. VAL VALOR Trial Design Consolidation (1-2 cycles) Study Arm First Relapsed or Refractory AML Vosaroxin + IDAC Induction (1-2 cycles) CR or CRp IDAC=intermediate-dose Ara-C; CR=complete remission; CRp=complete remission with incomplete platelet recovery; CRi=complete remission with incomplete recovery of platelets and neutrophils; PR=partial remission. If you treat AML, consider whether any of your patients are eligible y for enrollment in the VALOR trial. For more information, visit clini clinicaltrials.gov or www.valortrial.com, or contact Sunesis Clinical D Development at 888-71-VALOR or valortrial@sunesis.com. Smartphone users: take a picture of this image to visit the VALOR trial Website Reference 1. Roboz GJ, Lancet JE, Cripe LD, et a Results of a phase 2 pharmacokinetic/ al. pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Poster presented at: American Society of Clinical Oncology 2010 Annual Mee Meeting; June 4-8, 2010; Chicago, Illinois. Abstract 6526. 2. Data on file, Sunesis. Sunesis Pharmaceuticals, Inc. 395 Oyster Point Boulevard Suite 400 South San Francisco, CA 94080 Copyright © Sunesis Pharmaceuticals, Inc. 2010. Copyright © Sunesis Pharmaceuticals, Inc. 2011. All Rights Reserved. VOS-010-01 10/2011 Printed in USA 1:1 Randomization Survival Follow Up Control Arm Placebo + IDAC CRi, PR, or Treatment Failure  http://www.dobsonsrestaurant.com/home http://www.donovanssteakhouse.com http://www.cafe-21.com http://www.cafesevilla.com http://www.candelas-sd.com http://www.delmarrendezvous.com

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com